This US FDA approval extends the labeling claim to include detection of three additional gene EGFR
mutations L681Q, G719X and S768I to aid the identification of NSCLC patients for whom GILOTRIF (afatinib) is indicated.
Based on our review of the literature and data on EGFR
-targeted resistance to lung cancer, as well as on previous findings from our institution, seven target oncogenes ( EGFR
, KRAS , PIK3CA , BRAF , ERBB2 , NRAS , and BIM ) that are closely related to the targeted therapy resistance of the EGFR
gene were used in the polygenic primer panel.
Several distinct EGFR
activating mutations have been identified in lung adenocarcinomas.
5 months, which was shorter than the patients with common EGFR
mutations (median, 33.
3] exposure and induction of phosphorylation of EGFR
(Y1068) in HBEC.
About 10% of lung cancer patients have mutations in the EGFR
The Qiagen EGFR
Pyro Kit provides quantitative measurements of mutations in the EGFR
gene at codons, 719, 768, 790, 858, and 861, as well as deletions and complex mutations in exon 19.
Tarceva is already approved in Europe for use in advanced or metastatic NSCLC irrespective of a patient's EGFR
status both as maintenance therapy immediately after initial chemotherapy and when the disease has progressed following at least one course of chemotherapy.
The Boehringer Ingelheim LUX-Lung 3 trial studying BIBW 2992 in patients with EGFR
mutations will be important as we continue to work towards providing personalized medicine for patients with lung cancer," said James Yang, MD, PhD, Professor at the Graduate Institute of Clinical Medicine and the Graduate Institute of Clinical Pharmacy at the College of Medicine at the National Taiwan University (NTU).
The levels were even higher in tumors that had mutations in a gene called EGFR
, a common feature of lung cancer in never-smokers.
Two recent articles, Oishi (2008) in the Oncology Nursing Forum and Eaby, Culkin, and Lacouture (2008) in the Clinical Journal of Oncology Nursing, addressed nursing considerations for and management of patients experiencing EGFR
inhibitor-associated skin conditions.
In the first feature article, Christopher Jackson provides an overview of the biological basis for targeting EGFR
and highlights some of the important preclinical data relevant to gastrointestinal cancers.